Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5217957 | 0.85 | ALDH1A1 (0.49) | KMT2AMEN1LMNAALDH1A1ADORA2A | |
| SCHEMBL30525571 | 0.81 | HPGDS (0.48) | KMT2AMEN1ALDH1A1GLAHPGDS | |
| SCHEMBL29049509 | 0.81 | HPGDS (0.48) | KMT2AMEN1ALDH1A1GLAHPGDS | |
| SCHEMBL976186 | 0.74 | MEN1 (0.65) | KMT2AMEN1LMNAALDH1A1CDC7 | |
| SCHEMBL22573635 | 0.73 | GLA (0.59) | KMT2AMEN1LMNAADORA2AADORA1 | |
| SCHEMBL6016420 | 0.71 | MEN1 (0.61) | KMT2AMEN1LMNAALDH1A1CDC7 | |
| SCHEMBL15452663 | 0.70 | SMN1; SMN2 (0.47) | KMT2AMEN1LMNAALDH1A1ADORA2A | |
| SCHEMBL27873934 | 0.70 | P2RX7 (0.54) | KMT2ALMNAALDH1A1CYP1A2MAPT | |
| SCHEMBL31087643 | 0.70 | ALDH1A1 (0.62) | KMT2ALMNAALDH1A1CDC7DBF4 | |
| SCHEMBL28086048 | 0.70 | ALDH1A1 (0.62) | KMT2ALMNAALDH1A1CDC7DBF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392219-A4 | SUBSTITUTED N'-(ARYLCARBONYL)-BENZHYDRAZIDES, N'-(ARYLCARBONYL)-BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2007-01-24 | — | — | EP | disclosed |
| US-7074813-B2 | Substituted N′-(arylcarbonyl)-benzhydrazides, N′-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2006-07-11 | — | — | US | disclosed |
| US-20040186078-A1 | Substituted N'-(arylcarbonyl)-benzhydrazides, N'-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2004-09-23 | — | — | US | disclosed |
| US-6716859-B2 | ANTICANCER AGENTS | CYTOVIA, INC. | 2004-04-06 | — | — | US | disclosed |
| EP-1392219-A2 | SUBSTITUTED N'-(ARYLCARBONYL)-BENZHYDRAZIDES, N'-(ARYLCARBONYL)-BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030013743-A1 | Substituted N'-(arylcarbonyl)-benzhydrazides, N'-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-01-16 | — | — | US | disclosed |
| WO-2002089745-A2 | SUBSTITUTED N'-(ARYLCARBONYL)-BENZHYDRAZIDES, N'-(ARYLCARBONYL)-BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186078-A1 | Substituted N'-(arylcarbonyl)-benzhydrazides, N'-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP2, CASP1, BCL2 | KMT2A 2862/4885MEN1 2707/4885LMNA 809/4885 |
| US-20030013743-A1 | Substituted N'-(arylcarbonyl)-benzhydrazides, N'-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP2, CASP1, BCL2 | KMT2A 2862/4885MEN1 2707/4885LMNA 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.